WHERE HEALTH
INNOVATION BECOMES
INVESTABLE
WHERE HEALTH
INNOVATION
BECOMES
INVESTABLE
Some of Europe’s best health innovations keep failing not in the lab, but particularly on the way to the market. A market access with a plethora of investment opportunities. We fit somewhere in between, and beyond.
Thanks to our holistic approach, specialized knowledge, and constant focus (grounded in Evnia’s proven track record of turning regulatory and clinical complexity into market access for health innovators worldwide), we have created an exemplary portfolio that attracts founders and investors who see healthcare’s true dynamics.
We’re not here to chase trends — we’re here to support founders to dedicate themselves to the most meaningful work of their lives.
100+
Startups
50+
Operators
4
Countries
Our Story
ARETI Europe was founded on an observation: Europe’s most promising health innovations were failing not because of bad science, but because of the absence of the right infrastructure to carry them forward. This scenario kept repeating, to a degree we couldn’t ignore.
Our approach, choice of practices, even our name (the Greek word for Virtue), are a testament to our commitment: the full expression of one’s potential, while ensuring that potential is never lost to complexity. Shall we introduce the people behind that commitment?
Copenhagen
Aarhus
Thessaloniki
Riyadh
London
Copenhagen
Aarhus
Thessaloniki
Riyadh
London
Copenhagen
Aarhus
Thessaloniki
Riyadh
London
Copenhagen
Aarhus
Thessaloniki
Riyadh
London
Copenhagen
Aarhus
Thessaloniki
Riyadh
London
Copenhagen
Aarhus
Thessaloniki
Riyadh
London
Copenhagen
Aarhus
Thessaloniki
Riyadh
London
Copenhagen
Aarhus
Thessaloniki
Riyadh
London
Copenhagen
Aarhus
Thessaloniki
Riyadh
London
Copenhagen
Aarhus
Thessaloniki
Riyadh
London
Guiding Priciples
Our Foundation on business
A healthcare breakthrough may seem exciting. But what about its executable path to market penetration?
When it comes to regulated innovations, what matters is the operational capacity
to transform a technology from validated hypothesis to clearance, thereby making it acquisition-ready.
Guess who’s got it. But then again, you’re here, so there’s no need to guess further.
Where generalist VCs avoid what seems to them a regulatory and clinical entanglement, we project an opportunity.
By owning the hardest, most expertise-dependent phases of MedTech development, we turn barriers into structural advantages for both startups and investors.
Where others hesitate, we excel. As simple as that.
We operate within a deliberately narrow investment universe, dealing with a standard set of administrative frameworks, clinical evidence requirements, and market dynamics.
The results? Faster evaluation, earlier rejection of weak opportunities, and scalable execution without constantly reinventing the process wheel.
Our return model is built on multiple realistic exits rather than relying on a single unicorn outcome.
Strong, consistent performance is part of our portfolio’s structural design from day one. Hope or luck has no place in our approach, and to be honest, it shouldn’t have in yours either.
We are in the venture-building business, not the guessing game.
Our distinctive asset is the integrated platform behind every deal flow.
Our execution infrastructure (Venture Capital, Venture Studio, and Evnia Health Hub) creates a self-reinforcing system in which every investment round benefits from the same regulatory, clinical, and entrepreneurial advantages.
Success, on repeat. This is a core competence for us.
Corporate Advantage
No fund is an island. — ARETI’s partnerships with vertical stakeholders like hospitals, universities, regulators, corporates, and public institutions are considered a structural part of our modus operandi.
Every collaboration expands our clinical reach, deepens our regulatory intelligence, and broadens the ecosystem through which European health innovation becomes tangible solutions.
